
We Can No Longer Ignore The Value Of Caregiving
Every day, millions of Americans wake up to a second full-time job—a job they never applied for, never trained for, and receive no compensation for. While the role is rewarding in many ways, it grows more demanding by the day, often resulting in great personal and financial sacrifice.
Featured caregiver is a paid collaborator of Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc.
The conditions are ripe for burnout, with countless reports of depression, anxiety, and physical symptoms that manifest from chronic stress. As unbelievable as this job may seem, it's a reality for our country's 45 million unpaid caregivers. Despite their essential role in caring for their loved ones, they remain largely unseen. The sacrifices caregivers make are too often overlooked, leaving them without adequate training, financial support, or workplace protections that truly reflect their reality. But the longer we undervalue caregivers, the more the strain on all of us will continue.
Caregivers carry an immense responsibility, one that they should never have to shoulder alone. And yet, our healthcare system rarely offers another choice. It's devastating that even one caregiver should go without support, but the reality is so much worse. The failure to support caregivers ripples from individuals to communities, threatening the stability of our workforce, healthcare system, and economy.
As more caregivers are forced to leave their jobs or reduce their hours to care for their loved ones, businesses may face more turnover and less productivity. As more caregivers rely on their retirement funds, public assistance programs may face greater strain. And as caregivers' declining mental and physical health leads to increased medical needs, the overwhelmed facilities and uncompensated care costs could continue to burden a healthcare system that's already stretched thin.
Otsuka America Pharmaceutical, Inc.
Without more interventions, we may risk a future in which an aging population collides with an unsupported, unsustainable caregiving system—leaving families, businesses, and our government struggling to keep up.
As a healthcare company, Otsuka is in constant dialogue with the patients and caregivers that we serve. Recently, our conversations with caregivers have found recurring themes: a lack of assistance, a lack of understanding by employers, and, despite the abundance of caregivers, a surprising lack of societal awareness for their struggles. To better understand the scale of this inequity and communicate it to our industry peers, we collaborated with Columbia University Mailman School of Public Health to conduct a study of the current caregiver landscape. I expected the findings to be compelling, but they turned out to be staggering.
The report 'America's Unseen Workforce,' released in October 2024, revealed that 44.58 million US caregivers perform the equivalent of $873.5 billion worth of unpaid labor each year. That's $873,500,000,000. If family caregiving were a business entity, it would be the largest revenue-generating business in the world. But this 'company' isn't met with the excitement of an IPO or the urgency of a crashing stock—it's met with a shrug from those with the power to effectuate meaningful change.
Otsuka America Pharmaceutical, Inc.
Note: All company figures are as of June 30, 2024. These numbers will vary due to shifts in current market value.
The $873.5 billion figure demonstrates the magnitude of family caregiving, but the impact on individuals is also felt in real dollars. The report found that caregivers who begin their duties at a younger age are at risk of facing a 40% to 90% deficit in retirement savings by age 65 compared to non-caregivers, requiring an additional 7 to 21 years of work to recoup the equivalent savings. Our report also found that caregiving-induced declines in health contribute an estimated $28.3 billion annually in healthcare costs. With our country's aging population, these costs are only going to increase. Homeownership and retirement may be out of reach for many, and the dip in consumer spending could impact entire industries.
Despite the undeniable financial value that caregivers provide, protections that recognize their sacrifices are often absent from corporate benefits structures and national economic policies. Employers have the power—and the responsibility—to reshape how caregiving fits into the modern workplace. Comprehensive caregiver benefits, like flexible work arrangements, paid caregiver leave, and tailored mental health and financial planning resources, are essential. At Otsuka, we view these as investments not only in our employees but in our company's and society's futures. That's why we integrate our Caregiver Navigator program directly into our benefits structure—to ensure employees don't have to navigate these challenges alone—providing personalized care, emotional support, expert content, and local resources. It's our firm belief that the organizations that ignore these issues will be the first to fall behind.
That said, this goes far beyond work. Our national and state governments have a critical responsibility to aid caregivers and incentivize other sectors to do the same. Expanding caregiver tax credits and prioritizing payment, training, respite care, and health benefits programs would provide much-needed financial relief and contribute to more systemic change.
Featured caregiver is a paid collaborator of Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc.
At Otsuka, we believe that standing with caregivers isn't just the right thing to do—it's an economic and social imperative. Otsuka's commitment goes beyond our workforce, and it should go beyond yours, too. In addition to our caregiver benefits program in collaboration with ianacare and continued caregiver advocacy, we're the lead, founding sponsor of Caregiving, a two-hour documentary for PBS portraying paid and unpaid caregivers navigating the challenges and joys of this deeply meaningful work. Intertwining intimate personal stories with the untold history of caregiving, the documentary reveals the state and the stakes of care in America today. The project, created with executive producer Bradley Cooper, premieres June 24 on PBS and is available to stream on May 27 on PBS.org and the PBS App. It is the next feature film from the WETA award-winning Well Beings campaign, which addresses critical health needs in America.
This is more than an economic or political crisis—it's a human one. At some point, many of us will become caregivers—or rely on one to care for us. Businesses, policymakers, and individuals all have a role to play in ensuring that caregivers are not just seen but valued. We have a choice: Continue to let their contributions go unnoticed or recognize family caregiving as the essential work that it is. Allow millions to struggle in silence or step up and create a future where caregivers and their loved ones are not left behind. The question is: Will we create a society that tangibly supports caregivers or will we take them for granted?
Now is the time to act. I invite my fellow business leaders to join Otsuka in building a future where caregivers are seen, supported, and valued.
Discover our caregiver commitment.
Otsuka is a healthcare company driven by our purpose and defined by our beliefs. At Otsuka, we hold a deep respect for the value of every mind. We are dedicated to caring for caregivers—standing with them, the way they stand with their loved ones—and offering resources that may support their care for themselves and others. As we work to understand and share the stories of caregivers and support them on their journeys, we will continue advocating and calling for industry changes to improve their and their loved ones' quality of life.
April 2025 01US25EUC0188
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus


Newsweek
4 hours ago
- Newsweek
Egg Recall Map Shows Warnings Issued to Customers in 9 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. August Egg Company has issued a recall on Friday for 1,700,000 brown cage-free and certified organic brown eggs due to potential fears of salmonella. Newsweek reached out to the company after hours via phone Friday night for comment. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that salmonella is an organism that could cause serious and sometimes fatal infections in frail or older people, young children and those with weakened immune systems. What To Know The FDA says in its alert that some of the eggs were distributed to grocery stores including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs. Those eggs were distributed from February 3, 2025, to May 15, 2025, with sell by dates of March 4, 2025, and June 4, 2025, in both California and Nevada. The FDA says additional eggs were distributed from February 3, 2025, to May 6, 2025, with sell by dates of March 4, 2025, and June 19, 2025, in Walmart stores in Illinois, Indiana, Nebraska, New Mexico, California, Washington, Nevada, Arizona and Wyoming. The plant code numbers for the recalled eggs can be found printed on the package and are P-6562 or CA5330 with Julian Dates from 32 to 126, the FDA says. The Julian Dates are codes of three to seven digits and represent the date that the food was packaged or manufactured. "This recall is associated with an ongoing outbreak investigation of Salmonella Enteritidis illnesses" the alert says, adding the investigation is related to products distributed in the nine states. The FDA alert also has a chart of the Julian Dates with corresponding item names. What People Are Saying The FDA alert, in part: "August Egg Company is not selling fresh shell eggs at this time. Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens." August Egg Company in the FDA alert: "August Egg Company of Hilmar, CA is voluntarily recalling 1,700,000 dozen shell eggs processed at our California plant and sold to various grocery customers. This recall has been initiated due to possible Salmonella enteritidis contamination, which poses a health risk. With that in mind, we believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. "It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens. "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring. We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again." What Happens Next Customers with additional questions can call August Egg Company at 1-800-710-2554 from 9 a.m. and 5 p.m. PT and can also return the eggs to the original place of purchase for a refund.
Yahoo
4 hours ago
- Yahoo
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
Matthew Caufield, an analyst from H.C. Wainwright, initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) with a Buy rating and a $8 price target, on June 4. The analyst gave the optimistic rating due to the company's VAFSEO product and its potential in the CKD anemia market. VAFSEO is an approved treatment for anemia in adults with chronic kidney disease on dialysis. According to the analyst, the treatment is gaining considerable momentum among dialysis organizations, and this trend is anticipated to support near-term growth. He expects VAFSEO's ongoing launch to offset the effect of generics on AURYXIA, another product by Akebia Therapeutics, Inc. (NASDAQ:AKBA) that deals with hyperphosphatemia. A biopharmaceutical team in a laboratory analyzing new compounds to develop therapeutics. The analyst also reasoned that Akebia Therapeutics, Inc. (NASDAQ:AKBA) is positioned for success as it has secured contracts that cover almost all dialysis patients in the US. VAFSEO offers flexibility in its dosing regimen, ranging from 150mg to 600mg, making it a factor that allows for personalized treatment and potentially growing prescriptions. Caufield pointed out VAFSEO's oral administration as another reason supporting the optimistic rating, giving it an advantage over existing therapies, such as iron supplementation and erythropoiesis-stimulating agents. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is a biopharmaceutical company that develops and commercializes drugs to treat metabolic and renal diseases. While we acknowledge the potential of AKBA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio